Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886476 | 0.84 | SLC6A9 (0.46) | SLC6A9ALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL8278196 | 0.77 | HCRTR2 (0.43) | LMNAHCRTR2 | |
| SCHEMBL5501250 | 0.73 | ALDH1A1 (0.41) | SLC6A9ALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL3889138 | 0.73 | ALDH1A1 (0.44) | SLC6A9ALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL3893114 | 0.72 | SLC6A9 (0.79) | SLC6A9 | |
| SCHEMBL5504640 | 0.68 | ALDH1A1 (0.46) | SLC6A9ALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL4547019 | 0.68 | ALDH1A1 (0.61) | SLC6A9ALDH1A1LMNACYP2C9CYP1A2 | |
| SCHEMBL4177994 | 0.66 | SMN1; SMN2 (0.47) | LMNA | |
| SCHEMBL14417786 | 0.65 | ALDH1A1 (0.54) | ALDH1A1LMNACYP2C9 | |
| SCHEMBL995533 | 0.65 | GAA (0.38) | SLC6A9ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2005110983-A1 | AZETIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | SLC1A2, SLC18A2, SLC1A1 | SLC6A9 10/4885ALDH1A1 1719/4885LMNA 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.